Beth Belluscio, MD, PhD

Title: Global Clinical Lead, Rare Neurological Disorders

Organization: Pfizer

Bio: Beth achieved her MD-PhD in neurobiology at Columbia University. She is a is board certified Neurologist, having completed her residency at Duke University. After working at NIH for 10 years, she joined Pfizer and is the Global Clinical Lead for Neurological disorders within the Rare Disease group. She currently is focused on the effort to develop a gene therapy for Duchenne muscular dystrophy, overseeing all the clinical studies in this program.

2021 FUTURES: Gene Therapy & Gene Editing Symposium

Information and updates on the gene therapy and gene editing landscape from experts in the field.

**We experienced a technical issue during this session. Please reach out with questions to Futures@CureDuchenne.org if needed.

Beth Belluscio, MD, PhD

Global Clinical Lead, Rare Neurological Disorders

Pfizer

Olivier Danos, PhD

Chief Scientific Officer

REGENXBIO

Emil Kakkis, PhD

CEO & President

Ultragenyx Pharmaceutical

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

Carl Morris, PhD

Chief Scientific Officer

Solid Biosciences

Eric Olson, PhD

Chief Scientific Advisor

Vertex Pharmaceuticals

Matthew Pletcher, PhD

Division Head of Gene Therapy Research & Technical Operations

Astellas Gene Therapies

Deanna Tucker

Senior Medical Science Liaison

Sarepta Therapeutics

Genine Winslow, MSc

CEO & President

Chameleon Biosciences